To further confirm these results, we performed immunohistochemical staining and found that TRIM21 was overexpressed in 129 patients with cervical cancer (129/220, 58.64%), NCAPH was overexpressed in 84 patients (84/220, 38.18%), and beclin-1 was overexpressed in 156 patients (156/220, 70.91%) (Supplementary Fig. S2D). Here, TRIM21 is linked to cervical cancer.